Treatment of patients with advanced cancer with the natural killer cell line NK-92

Cytotherapy

Volumn 15, Issue 12, 2013, Pages 1563-1570

  Tonn, Torsten ^a,b   Schwabe, Dirk ^a   Klingemann, Hans G ^c   Becker, Sven ^a,b   Esser, Ruth ^a,e   Koehl, Ulrike ^a,e   Suttorp, Meinolf ^d   Seifried, Erhard ^a,b   Ottmann, Oliver G ^a   Bug, Gesine ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b German Red Cross Blood Donation Service   (Germany)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cancer; Cellular immunotherapy; Natural killer cell; NK 92; Phase I clinical trial

Indexed keywords

LEUKOCYTE ANTIBODY; LEUKOCYTE ANTIGEN; MORPHINE; RECOMBINANT INTERLEUKIN 2;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CELL EXPANSION; CELL ISOLATION; CELL STRAIN NK 92; CELL THERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LEUKEMIA; LOW BACK PAIN; LUNG CANCER; LYMPHOCYTE TRANSFER; LYMPHOMA; MALE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SARCOMA; SCHOOL CHILD; SOLID TUMOR; TREATMENT RESPONSE; Y CHROMOSOME;

CANCER; CELLULAR IMMUNOTHERAPY; NATURAL KILLER CELL; NK-92; PHASE I CLINICAL TRIAL;

ADOLESCENT; ADULT; AGED; CELL- AND TISSUE-BASED THERAPY; CHILD; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOID; MALE; MIDDLE AGED; NEOPLASM STAGING; SARCOMA; TRANSPLANTATION, HOMOLOGOUS;

EID: 84887052348     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.06.017     Document Type: Article

References (42)

1. Klingemann H. Cellular therapy of cancer with natural killercells: where do we stand? Cytotherapy. 2013;June 12:1465-3249.
2. Kolb H.-J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
3. Dazzi F., Szydlo R.M., Craddock C., Cross N.C., Kaeda J., Chase A., et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000, 95:67-71.
4. Horowitz M.M., Gale R.P., Sondel P., Goldmann J.M., Kersey J., Kolb H.J., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
5. Lanier L.L. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008, 9:495-502.
6. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., et al. Innate or adaptive immunity? The example of natural killer activating ligands on myeloid cells. Science 2011, 331:44-49.
7. Ruggeri L., Campanni M., Casucci M., Volpi I., Tosti A., Perruccio K., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333-339.
8. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
9. Cooley S., Weisdorf D.J., Guethlein L.A., Klein J.P., Wang T., Le C.T., et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
10. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
11. Passweg J.R., Stern M., Koehl U., Uharek L., Tichelli A. Use of natural killer cells in hematopoietic stem cell transplantation. Bone Marrow Transplant 2005, 35:637-643.
12. Klingemann H., Grodman C., Cutler E., Duque M., Kadidlo D., Klein A., et al. Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell enriched infusions. Transfusion 2013, 53:412-418.
13. Koepsell S.A., Miller J.S., McKenna D.H. Natural killer cells: a review of manufacturing and clinical utility. Transfusion 2012, 53:404-410.
14. Parkhurst M.R., Riley J.R., Dudley M.E., Rosenberg S.A. Adoptively transferred autologous natural killer cells persist in circulation but do not mediate tumor regression. Clin Cancer Res 2011, 17:6287-6297.
15. McKenna D.H., Sumstad D., Bostrom N., Kadidlo D.M., Fautsch S., McNearney S., et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six year single-institution experience. Transfusion 2007, 47:520-528.
16. Klingemann H.-G., Martinson J. Ex vivo expansion of naturalkiller cells for clinical application. Cytotherapy 2004, 6:15-22.
17. Yengar R., Handgretinger R., Babarin-Dorner A., Leimig T., Otto M., Geiger T.L., et al. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 2003, 5:479-484.
18. Gong J.H., Maki G., Klingemann H.G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994, 8:652-658.
19. Klingemann H.-G., Wong E., Maki G. Acytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant 1996, 2:68-75.
20. Tam Y.K., Miyagawa B., Ho V.C., Klingemann H.-G. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. JHematother 1999, 8:281-290.
21. Yan Y., Steinherz P., Klingemann H.-G., Denning D., Childs B.H., McGuirk J., et al. Antileukemia activity of a natural killer cell line against human leukemia. Clin Cancer Res 1998, 4:2859-2868.
22. Maki G., Klingemann H.-G., Martinson J.A., Tam Y.K. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. JHematoth Stem Cell Res 2001, 10:369-383.
23. Tam Y., Martinson J.A., Doligosa K., Klingemann H.-G. Ex vivo expansion of the highly cytotoxic human NK-92 cell line under cGMP conditions for clinical adoptive cellular immunotherapy. Cytotherapy 2003, 5:259-272.
24. Arai S., Meagher R., Swearingen M., Myint H., Rich E., Martinson J., et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008, 10:625-632.
25. Tonn T., Becker S., Esser R., Schwabe D., Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. JHematother Stem Cell Res 2001, 10:535-544.
26. Eisenhauer E.A., Therasse P., Bogaerts L.H., Schartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
27. Grossi F., Sini C., Barletta G., Rijavec E., Genova C., Dal Bello M.G., et al. The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib as the second/third line. JClin Oncol 2012, 30(suppl abstract): 7577).
28. Bhat R., Watzl C. Serial killing of tumor cells by human natural killer cells: enhancement by therapeutic antibodies. PLOS One 2007, e326.
29. Daldrup-Link H.E., Meier R., Rudelius M., Piontek G., Piert M., Metz S., et al. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol 2005, 15:4-13.
30. Smyth M.J., Teng M.W., Swann J., Kyparissoudis K., Godfrey D.I., Hayakawa Y. CD4+CD25+ T-regulatory cells suppress NK cell-mediated immunotherapy of cancer. JImmunol 2006, 176:1582-1587.
31. Klebanoff C.A., Khong H.T., Antony P.A., Palmer D.C., Restifo N.P. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor Immunotherapy. Trends Immunol 2005, 26:111-117.
32. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. JClin Oncol 2008, 26:5233-5239.
33. Uherek C., Tonn T., Uherek B., Becker S., Schnierle B., Klingemann H., Wels W. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002, 100:1265-1273.
34. Boissel L., Betancur M., Wels W.S., Tuncer H., Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res 2009, 33:1255-1259.
35. Romanski A., Uherek C., Bug G., Muller T., Rossig C., Kampfmann M., et al. Re-targeting of an NK cell line (NK-92) with specificity for CD19 efficiently kills human B-precursor leukemia cells. Blood 2004, 104:751a.
36. Mueller T., Uherek C., Maki G., Chow K.U., Klingemann H.-G., Tonn T., et al. Expression of a CD20 specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of leukemia and lymphoma cells. Cancer Immunol Immunother 2008, 57:411-423.
37. Yang S., Xin A., Brown R.D., Ho J., Gibson J., Joshua D.E. Development of retargeted CD38 specific NK-92 cell line for potential anti-myeloma immunotherapy. Blood 2005, 106:5104. (abstract).
38. Esser R., Mueller T., Stefes D., Kloess S., Seidel D., Gillies S.D., et al. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC like activity against tumor cells of neuroectodermal origin. JCell Mol Med 2012, 16:569-581.
39. Sahm C., Schoenfeld K., Wels W.S. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother 2012, 61:1451-1461.
40. Tassev D.V., Cheng M., Cheung N.K. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther 2012, 19:84-100.
41. Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T., Klingemann H.-G. Characterization of genetically altered, interleukin 2 independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther 1999, 10:1359-1373.
42. Binyamin L., Alpaugh R.K., Hughes T.L., Lutz C.T., Campbell K.S., Weiner L.M. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. JImmunol 2008, 180:6392-6401.